相关实验视频

Updated: May 5, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

美国成年人中肝炎C诊断测试方法的成本效益分析

Eric W Hall¹, Amy L Sandul², Saleem Kamili²

¹OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, Oregon, USA.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

|May 21, 2025

概括

病毒-首先型肝炎病毒 (HCV) 测试策略改善了诊断和健康结果. 与目前的方法相比,这些方法具有成本效益,增加了HCV诊断和治疗机会.

科学领域:

肝病学肝病学是一种肝病学.
公共卫生公共卫生
卫生经济学卫生经济学

背景情况:

美国许多成年人仍然不知道他们感染了C型肝炎病毒 (HCV),这阻碍了获得治愈治疗的机会.
首先对病毒进行测试的策略为改善HCV诊断率提供了潜在的解决方案.
目前的HCV测试算法需要对较新的策略进行成本效益评估.

研究的目的:

评估新型病毒-首先HCV检测策略的成本效益.
将这些策略与当前标准的HCV检测算法进行比较.
评估对HCV诊断,治疗和患者健康结果的影响.

主要方法:

使用马尔科夫模型的决策树框架模拟了美国成年人队列中的HCV疾病进展.
模拟了四种测试策略:当前标准 (比较器),基于HCVcAg的 (干预1) 同步抗HCV/HCVcAg (干预2) 和仅NAT (干预3).
成本,质量调整后寿命年 (QALYs) 和流行病学结果在一生的时间范围内进行了比较.

主要成果:

干预1 (基于HCVcAg) 在诊断和结果方面与比较器相匹配,但每人节省了0.26美元.
干预措施2和3的成本更高 (分别为每人8.60美元和21.48美元).
干预措施2和3都显示,与对照组相比,HCV诊断,治疗感染和QALY增加.

结论:

与目前的方法相比,病毒第一的HCV检测策略可能具有成本效益.
这些策略可以在HCV诊断和改善患者健康结果方面取得重大进展.
实施病毒第一检测可能会提高获得及时和治愈性HCV治疗的机会.

关键词:

美国的美国.分析成本效益分析.诊断诊断诊断诊断诊断诊断流行病学流行病学型肝炎C型肝炎的发生

更多相关视频

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.